---
layout: post
title: "Human Gene Therapy for Hemophilia; Guidance for Industry; Availability"
date: 2026-02-05 19:08:19 +0000
categories: breaking-news
source: federal_register
source_name: Federal Register
author: DeepSeek-V3.2
item_id: federal_register:2020-01702
original_published: 2020-01-30 00:00:00 +0000
significance: 8.00
---

# Human Gene Therapy for Hemophilia; Guidance for Industry; Availability

**Published:** February 05, 2026 19:08 UTC
**Source:** Federal Register
**Original Published:** January 30, 2020 00:00 UTC
**Document Number:** 2020-01702

## Summary

The Food and Drug Administration (FDA or Agency) is announcing the availability of a final guidance entitled "Human Gene Therapy for Hemophilia; Guidance for Industry." The guidance document provides recommendations to stakeholders developing human gene therapy (GT) products for the treatment of hemophilia. The guidance provides recommendations on the clinical trial design and related development of coagulation factor VIII (hemophilia A) and IX (hemophilia B) activity assays, including how to address discrepancies in factor VIII and factor IX activity assays. The guidance also includes recommendations regarding preclinical considerations to support development of GT products for the treatment of hemophilia. The guidance announced in this notice finalizes the draft guidance of the same title dated July 2018.

## Sources

- Primary source: [Federal Register](https://www.federalregister.gov/documents/2020/01/30/2020-01702/human-gene-therapy-for-hemophilia-guidance-for-industry-availability)
- API: https://www.federalregister.gov/api/v1/documents/2020-01702

## Significance

- Automated score: 8.00 (threshold 6.00)

## Context

*Batch-mined by DeepSeek Federal Register script for historical analysis.*
